11 min read
Monthly FDA Guidance and Regulatory News Review - September 2026
This September 2026 regulatory update focuses on FDA’s new guidance on neonatal parenteral nutrition compounding and...
Meet Veristat in Basel at the Swiss Biotech Day, 22-23 April 2024
With nearly 30 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program.
If you are transitioning your compound into clinical trials, you need the right partner to guide your planning and decision-making. Whether you are preparing your IND/CTA, or you are looking to recruit patients quickly to get your early phase trials running, or just need medical writing, biostatistical,or pharmacovigilance support for your programs – Veristat can help.
As a flexible CRO and consultancy, we provide impactful solutions on a full-service or functional service basis, integrating strategic planning, regulatory expertise, and clinical trial execution to rapidly advance the most complex or novel therapies. Our acquisition of SFL extends our capabilities into public affairs, market access, and healthcare compliance, with team members deeply embedded in the EU, UK and Swiss healthcare ecosystem.
Don't miss this opportunity to connect with us and learn more about how Veristat is making a difference in the lives of patients with rare and ultra-rare diseases.
Where Data Becomes Direction for complex clinical programs.
Schedule A Meeting
Veristat team member, Delphine Guérin, Senior Business Development Director, will be at the venue, ready to listen to your needs and share Veristat’s expertise.
You can arrange a meeting by completing the form on the right side of this page. Explore our wide range of capabilities and discover how we can advance your programs to a successful outcome.
Conference Details
Website: SWISS BIOTECH DAY
Schedule A Meeting
Meet with us at Swiss Biotech Day 2024 by filling out the form below.
8 min read
Monthly FDA Guidance and Regulatory News Review - August 2026
Sep 21, 2026 Veristat Blog
This August 2026 regulatory update focuses on the FDA finalizing three guidances addressing formal sponsor meetings,...